Page One

Mayors Try to Persuade Bayer to Stay in East Bay

By Rio Bauce Special to the Planet
Thursday August 13, 2009 - 10:59:00 AM

Berkeley officials confirmed Friday that plans are in the works to try to provide tax incentives to Bayer, the city’s largest private-sector employer, to keep the company from leaving the city.  

According to East Bay officials, Bayer Healthcare could decide within two weeks whether to relocate or commence manufacturing the next generation of Kogenate, a drug for the treatment of hemophilia, at their 43-acre campus next to the Berkeley Aquatic Park. 

Senior company officials plan to make the case to the Bayer AG Governing Board that the company should stay in Berkeley.  

In an effort to retain the company, the mayors of Berkeley, Oakland and Emeryville are collaborating to expand Oakland’s enterprise zone to include West Berkeley. An enterprise zone is a state-mandated area that gives companies tax credits to hire and train workers.  

On July 28 the Oakland City Council unanimously approved a motion to ask the state to include West Berkeley businesses within Oakland’s enterprise zone. If the cities succeed in getting Bayer included within the zone, the company could receive as much as $19 million in benefits over a 10-year period, including $13 million in tax incentives, $1.5 million in worker-training reimbursements, and $4.5 million in reduced electric rates from PG&E.  

The East Bay Development Alliance, an organization that lobbies to increase jobs and improve economic activity in the East Bay, assembled the package of economic incentives for Bayer that includes the reduced PG&E rates. 

Officials from the East Bay Development Alliance could not be reached for comment by press time. 

Berkeley Mayor Tom Bates, Oakland Mayor Ron Dellums, and Emeryville Mayor Richard Kassis sent a joint letter to Bayer board member Hartmut Klusik last month urging the company to remain in Berkeley. 

“We recognize that Bayer, as a publicly traded corporation, must make location decisions based in part on cost considerations,” the letter said. “Therefore, the cities are working with the state to create a powerful set of economic incentives.” 

Although the cities may all agree to expand the enterprise zone, the final decision is up to state officials.  

Bayer officials are reluctant to speak about the issue before scheduled meetings among top company officials in Germany. 

Company spokeswoman Trina Ostrander issued a statement late Friday. 

“Bayer is proud of its long-standing commitment to the Bay Area, and especially our 30-year Development Agreement with the City of Berkeley,” said Bayer spokeswoman Trina Ostrander. “We value our local ties and have continuously worked to enrich the communities in which we operate and live.”  

Ostrander said that expenses would be a major factor in their considerations. 

“We cannot forget that by various indicators doing business in California is very expensive,” said Ostrander. “To strengthen the economic diversity of the East Bay and encourage the growth of the biotech sector and green corridor requires forward-looking economic development strategies such as Enterprise Zones. We are currently exploring various options, however at this point it is premature to provide any speculation on future plans.” 

Berkeley city officials are anxiously waiting for Bayer’s decision. 

“We are fearful that any step to move production of Kogenate could mean a move out of Berkeley,” said Michael Caplan, the city’s economic development manager. “We are doing everything within our power to get them to stay here.” 

Caplan explained that expanding the enterprise zone is a regional issue, citing his office’s statistics, which show that most Bayer workers live outside of Berkeley and 3,000 Oakland residents work in West Berkeley. 

Founded in 1863, Bayer, based in Barmen, Germany, is the third-largest pharmaceutical company in the world. 

Bayer’s Berkeley campus is the company’s global center for hemophilia and cardiology pharmaceuticals, including Kogenate. CNN reported that in January 2001, the FDA halted shipments of Kogenate FS after it was found that harmful bacteria were present in the drug’s manufacturing process.